#BNCT (Courtesy: TAE Life Sciences) Boron neutron capture therapy (BNCT) delivers targeted radiation directly into tumour cells, with minimal damage to healthy tissue. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide. The first, as Bruce Bauer, chief executive of its subsidiary TAE Life Sciences explained to The Engineer, is simply that it offers the opportunity to treat previously intractable forms of the disease. The new Joint-Venture is expected to expand Neuboron Therapy System’s global influence and speed up the deployment of NeuPexTM for the benefit of cancer patients globally. The participation of TAE Life Sciences will strengthen NTS’s supply chain for its NeuPexTM, NTS’s accelerator-based Boron Neutron Capture Therapy (AB-BNCT) system. For California-based TAE Technologies, cancer treatments are a goal with twin advantages. TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. It offers the potential to treat micrometastases that can’t be visualized on medical images and typically requires just one or two treatment sessions. At TAE Life Sciences, our mission is to advance Boron Neutron Capture Therapy (BNCT). TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells. TAE Life Sciences (TLS) today announces a new joint venture (JV) agreement with Neuboron Medtech (Neuboron) for the widespread adoption of Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) for the treatment of invasive, recurrent and difficult to treat cancers.Under the agreement, TLS becomes the second shareholder in Neuboron Therapy System (NTS), originally … 267 likes. Breakthrough medical technology for treating cancers while sparing healthy tissue. FOOTHILL RANCH, Calif.--(BUSINESS WIRE)--Dec 8, 2020--TAE Life Sciences (TLS) today announces a new joint venture (JV) agreement with Neuboron Medtech (Neuboron) for the widespread adoption of Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) for the treatment of invasive, recurrent and difficult to treat cancers.Under the agreement, TLS becomes the … Neuboron Medtech, a BNCT total solution provider, enters Joint-Venture Agreement with TAE Life Sciences, further consolid Neuboron Therapy System (NTS), a wholly owned subsidiary of Neuboron Medtech, announced today it has approved an approximate USD 10 million of minority equity investment from TAE Life Sciences (TLS), a US-based leading manufacturer of Vacuu Neuboron Medtech Ltd …